Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma

Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma

Abstract Background Transformation to small cell lung cancer (SCLC) is a resistance mechanism of epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma (LADC) patients treated with EGFR tyrosine kinase inhibitors (TKIs). Here, we describe the clinical characteristics and prognosis of the...

Full description

Bibliographic Details
Main Authors:	Shouzheng Wang, Tongji Xie, Xuezhi Hao, Yan Wang, Xingsheng Hu, Lin Wang, Yan Li, Junling Li, Puyuan Xing
Format:	Article
Language:	English
Published:	Wiley 2021-10-01
Series:	Thoracic Cancer
Subjects:	anti‐angiogenesis epidermal growth factor receptor mutation lung adenocarcinoma small cell histological transformation tyrosine kinase inhibitors
Online Access:	https://doi.org/10.1111/1759-7714.14144

Similar Items

De Novo T790M Mutation in an L858R Epidermal Growth Factor Receptor Mutant-Associated Lung Adenocarcinoma
by: Takumi Fujiwara, et al.
Published: (2020-10-01)

Concurrent chemotherapy and first‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first‐line treatment in advanced lung adenocarcinoma harboring an EGFR mutation
by: Ziyi Xu, et al.
Published: (2021-08-01)

A case with psoriasis-like lesions induced by olmutinib (HM61713) while treating epidermal growth factor receptor T790M mutant advanced lung adenocarcinoma
by: Chu-Ju Hung, et al.
Published: (2019-01-01)

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
by: Ping-Chih Hsu, et al.
Published: (2020-10-01)

Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery
by: Tetsuya Isaka, et al.
Published: (2018-10-01)

Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation
by: Patel N, et al.
Published: (2017-06-01)

Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in EGFR-Mutant Lung Adenocarcinoma
by: Teng Li, et al.
Published: (2021-05-01)

Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations
by: Song X, et al.
Published: (2017-06-01)

Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor
by: Xie Y, et al.
Published: (2021-10-01)

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
by: Sojung Park, et al.
Published: (2021-01-01)

Estrogen Receptor β1 Expression Patterns Have Different Effects on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors’ Treatment Response in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma
by: Lijuan Zhang, et al.
Published: (2021-01-01)

Relationship of epidermal growth factor receptor activating mutations with histologic subtyping according to International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society 2011 adenocarcinoma classification and their impact on overall survival
by: Venkata Nagarjuna Maturu, et al.
Published: (2016-01-01)

Efficacy of Chemotherapy after EGFR-TKIs Resistance in 191 Patients with Unknow EGFR Gene Mutation in Advanced Lung Adenocarcinoma
by: Ping HE, et al.
Published: (2013-10-01)

Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
by: Zhengyu Yang, et al.
Published: (2021-08-01)

A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition
by: Nana Zhang, et al.
Published: (2017-01-01)

T790M mutations identified by circulating tumor DNA test in lung adenocarcinoma patients who progressed on first-line epidermal growth factor receptor-tyrosine kinase inhibitors
by: Vinodini Merinda, et al.
Published: (2020-01-01)

EGFR-TKI plus bevacizumab as maintenance therapy for advanced lung adenocarcinoma: a retrospective study of 192 cases
by: HU Xueting, et al.
Published: (2021-04-01)

Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma
by: Li C, et al.
Published: (2019-04-01)

Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
by: Ming-Ju Tsai, et al.
Published: (2018-11-01)

Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer
by: Zhang H
Published: (2016-11-01)

Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations
by: Zhang R, et al.
Published: (2016-01-01)

Epidermal growth factor receptor and anaplastic lymphoma kinase mutation in adenocarcinoma lung: Their incidence and correlation with histologic patterns
by: Pankaj Gupta, et al.
Published: (2019-01-01)

Histologic Grade Is Predictive of Incidence of Epidermal Growth Factor Receptor Mutations in Metastatic Lung Adenocarcinoma
by: Michelle Levy, et al.
Published: (2017-12-01)

Clinical outcomes of epidermal growth factor receptor tyrosine kinase inhibitors in recurrent adenosquamous carcinoma of the lung after resection
by: Fan L, et al.
Published: (2017-01-01)

Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis
by: Limin CHEN, et al.
Published: (2019-05-01)

Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases
by: Soomin Ahn, et al.
Published: (2016-07-01)

Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study
by: Dinesh Chandra Doval, et al.
Published: (2013-01-01)

Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
by: Eun Young Kim, et al.
Published: (2018-12-01)

Poorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitor
by: Yang CJ, et al.
Published: (2016-03-01)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
by: Shih-Chieh Chang, et al.
Published: (2011-06-01)

Computed Tomography Morphological Classification of Lung Adenocarcinoma and Its Correlation with Epidermal Growth Factor Receptor Mutation Status: A Report of 1075 Cases
by: Li Q, et al.
Published: (2021-07-01)

Prognostic value of localization of epidermal growth factor receptor in lung adenocarcinoma
by: Jinn-Li Wang, et al.
Published: (2018-06-01)

Expression of Axl in Lung Adenocarcinoma and Correlation with Tumor Progression
by: Yi-Shing Shinh, et al.
Published: (2005-12-01)

Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma
by: Hui ZHANG, et al.
Published: (2015-11-01)

Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
by: Laksmi Wulandari, et al.
Published: (2018-07-01)

Case Report: Re-Sensitization to Gefitinib in Lung Adenocarcinoma Harboring EGFR Mutation and High PD-L1 Expression After Immunotherapy Resistance, Which Finally Transform Into Small Cell Carcinoma
by: Xiaoqian Zhai, et al.
Published: (2021-06-01)

Multiple primary lung adenocarcinomas pre‐operatively diagnosed by discordant epidermal growth factor receptor mutations
by: Yuki Katayama, et al.
Published: (2019-08-01)

A Review of EGFR-TKIs Therapy of Non-small Cell Lung Cancer with Uncommon EGFR Mutations
by: Wenxing DU, et al.
Published: (2019-09-01)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
by: Yuan Ying, et al.
Published: (2012-11-01)

Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer
by: Giuliano Palumbo, et al.
Published: (2020-04-01)